Association of BMI and HDL Cholesterol in Relation to Intermediate Glycaemic Marker Glycated Albumin in Type 2 Diabetes Mellitus BC07-BC10
Dr. Suresh Babu Kondaveeti,
Associate Professor, Department of Biochemistry, SMCW, SIU, Lavale, Pune-412115, Maharastra, India.
Introduction: The main issue with the morbidity and mortality of type 2 diabetes is its associated health complications. In the last decade Glycated Albumin (GA) emerged as an extinguished marker for short-term glycaemic control.
Aim: To Quadrate the association of Body Mass Index (BMI) along with HDL-cholesterol to GA in Type 2 diabetic cases.
Materials and Methods: Total of 50 diabetic cases (Group 1) and 50 healthy non-diabetic control subjects (Group 2) recruited for the study between November 2017 to December 2018, which includes both males and females. Serum samples of both the groups were analysed to assess the lipid profile to GA levels along with BMI. Variations among groups was compared using student t-test by calculating r-values of the parametres and the pearson coefficient was calculated with significant p value at <0.05.
Results: The levels of HDL cholesterol in group 1 when compared with group 2 were significantly lower. Both BMI and GA showed negative correlation with HDL-C levels in both the groups. (p values 0.051 and 0.331 respectively). To boot, there was a statistically undeviating reciprocity of LDL-cholesterol to GA levels, BMI to LDL-cholesterol, and BMI to Triglycerides (TG). There was a statistically significant correlation between GA and BMI (r=0.240, p<0.0001) and there was a statistically significant negative correlation between GA and HDL-cholesterol (r=-0.286, p<0.051) in diabetic patients (group 1). The association between GA and LDL-cholesterol (r=0.271, p<0.0001) was also been found statistically significant in group 1.
Conclusion: The present study suggests that GA can be adapted as a reliable prospective biomarker that endures the potentiality in prognostication of serum lipid levels in diabetic patients and also BMI is the key formidable feature of dyslipidemia in type 2 diabetic cases.